Raymond James Downgrades UserTesting to Market Perform
Raymond James analyst Brian Peterson downgrades UserTesting (NYSE:USER) from Strong Buy to Market Perform.
Guggenheim Downgrades Horizon Therapeutics to Neutral, Raises Price Target to $116.5
Guggenheim analyst Yatin Suneja downgrades Horizon Therapeutics (NASDAQ:HZNP) from Buy to Neutral and raises the price target from $98 to $116.5.
B of A Securities Downgrades Synchrony Finl to Neutral
B of A Securities analyst Mihir Bhatia downgrades Synchrony Finl (NYSE:SYF) from Buy to Neutral.
JMP Securities Downgrades Sabra Health Care REIT to Market Perform
JMP Securities analyst Aaron Hecht downgrades Sabra Health Care REIT (NASDAQ:SBRA) from Market Outperform to Market Perform.
Keefe, Bruyette & Woods Downgrades Independent Bank to Market Perform, Announces $100 Price Target
Keefe, Bruyette & Woods analyst Christopher Mcgratty downgrades Independent Bank (NASDAQ:INDB) from Outperform to Market Perform and announces $100 price target.
Keefe, Bruyette & Woods Downgrades Independent Bank to Market Perform, Announces $26 Price Target
Keefe, Bruyette & Woods analyst Christopher Mcgratty downgrades Independent Bank (NASDAQ:IBCP) from Outperform to Market Perform and announces $26 price target.
Keefe, Bruyette & Woods Downgrades American National to Market Perform, Announces $42 Price Target
Keefe, Bruyette & Woods analyst Christopher Mcgratty downgrades American National (NASDAQ:AMNB) from Outperform to Market Perform and announces $42 price target.
Keefe, Bruyette & Woods Downgrades F N B to Market Perform, Lowers Price Target to $15.5
Keefe, Bruyette & Woods analyst Christopher Mcgratty downgrades F N B (NYSE:FNB) from Outperform to Market Perform and lowers the price target from $16 to $15.5.
Keefe, Bruyette & Woods Downgrades Heartland Financial USA to Market Perform, Announces $54 Price Target
Keefe, Bruyette & Woods analyst Christopher Mcgratty downgrades Heartland Financial USA (NASDAQ:HTLF) from Outperform to Market Perform and announces $54 price target.
Keefe, Bruyette & Woods Downgrades Home BancShares to Market Perform, Announces $28 Price Target
Keefe, Bruyette & Woods analyst Christopher Mcgratty downgrades Home BancShares (NYSE:HOMB) from Outperform to Market Perform and announces $28 price target.